Momelotinib 100 mg, 150 mg, 200 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 100 mg, 150 mg, 200 mg

Reference Brands: Ojjaara (USA)

Category: Oncology Cancer Care

Momelotinib tablets (100–200 mg) are a JAK1/JAK2 inhibitor for myelofibrosis with anaemia, and it can reduce transfusion needs. It is made by GSK as Ojjaara (US) and Omjjara (EU) and is a patented innovator product. Supply is through authorised distribution or named-patient import; ask us which route fits your country.

Product Description:

Momelotinib is an oral anticancer medication used for the treatment of myelofibrosis, a rare bone marrow disorder characterized by abnormal blood cell production, splenomegaly, and anemia. It is marketed under the brand name Ojjaara and belongs to the class of Janus kinase (JAK) inhibitors. Momelotinib works by inhibiting JAK1 and JAK2 signaling pathways involved in inflammation and abnormal cell proliferation, while also modulating pathways related to anemia, making it a differentiated therapy for patients with myelofibrosis.

Momelotinib is indicated for adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis and secondary myelofibrosis arising from polycythemia vera or essential thrombocythemia. The medication is administered orally, offering convenience for long-term disease management.

Common adverse reactions associated with momelotinib therapy include dizziness, fatigue, diarrhea, nausea, thrombocytopenia, hemorrhage, and bacterial infections. Due to these potential effects, patients receiving momelotinib require regular clinical and laboratory monitoring. Overall, momelotinib provides an important targeted treatment option for managing myelofibrosis, particularly in patients with disease-related anemia, supporting improved symptom control and quality of life.